Results 81 to 90 of about 31,914 (284)

Non-vitamin K antagonist oral anticoagulation agents in anticoagulant naive atrial fibrillation patients [PDF]

Europace, 2014
This editorial refers to ‘Non-vitamin K antagonist oral anticoagulation agents (NOACs) in anticoagulant naive atrial fibrillation patients: Danish Nationwide Descriptive Data 2011–2013’ by J.B. Olesen et al ., on page 187–193. Atrial fibrillation (AF) is the commonest cardiac rhythm disorder and is associated with an increased risk of mortality and ...
openaire   +2 more sources

Clinical pharmacology and prescribing education: An updated medical school curriculum from the British Pharmacological Society

British Journal of Clinical Pharmacology, EarlyView.
Aims Prescribing is a complex, essential skill that doctors must acquire to practice medicine safely and effectively. The British Pharmacological Society has historically provided a core curriculum to guide clinical pharmacology and prescribing education in UK medical schools.
Dagan O. Lonsdale, Clare Guilding, Jennifer Koenig, Michael Okorie, Reecha Sofat, Simon Maxwell   +5 more
wiley   +1 more source

Recanalization of Thrombosed Atrial Flow Regulator in Failing Fontan: A Bridge to Transplant

Catheterization and Cardiovascular Interventions, EarlyView.
ABSTRACT We report the case of a 10‐year‐old boy (41 kg, 133 cm) with hypoplastic left heart syndrome (mitral and aortic atresia), who underwent staged palliation: Norwood‐Sano at 6 days, Glenn at 7 months, and Fontan completion at 3 years using a 16 mm non‐fenestrated extracardiac Gore‐Tex conduit.
Raymond N. Haddad, Estibaliz Valdeolmillos, Emre Belli, Sébastien Hascoët   +3 more
wiley   +1 more source

Safety of Non-Vitamin K Antagonist Oral Anticoagulant Treatment in Patients with Chronic Kidney Disease and Kidney Transplant Recipients

Transplantology, 2022
The use of novel oral anticoagulants in patients with impaired renal function or undergoing immunosuppressive therapy is limited due to the risk of drug-to-drug interactions and anticoagulation-related adverse events.
Mikołaj Młyński, Mikołaj Sajek, Zbigniew Heleniak, Alicja Dębska-Ślizień   +3 more
doaj   +1 more source

Patient-Reported Satisfaction and Study Drug Discontinuation: Post-Hoc Analysis of Findings from ROCKET AF. [PDF]

, 2019
IntroductionPatient-reported outcomes (PROs) and satisfaction endpoints are increasingly important in clinical trials and may be associated with treatment adherence.
Becker, Richard C, Berkowitz, Scott D, Breithardt, Guenter, Fox, Keith AA, Hacke, Werner, Halperin, Jonathan L, Hankey, Graeme J, Hellkamp, Anne S, Mahaffey, Kenneth W, Nessel, Christopher C, Patel, Manesh R, Piccini, Jonathan P, Rodriguez, Fatima, Singer, Daniel E, Ungar, Leo   +14 more
core   +1 more source

Special considerations for therapeutic choice of non-vitamin K antagonist oral anticoagulants for Japanese patients with nonvalvular atrial fibrillation. [PDF]

, 2017
Nonvalvular atrial fibrillation (AF) is a risk factor for stroke in elderly patients. Although warfarin has been used to prevent AF-associated stroke for more than 50 years, non-vitamin K antagonist oral anticoagulants (NOACs) including dabigatran ...
Alexander, Ansell, Bathala, Camm, Connolly, Connolly, Eriksson, Giugliano, Goto, Granger, Harder, Heidbuchel, Hori, Hori, JCS Joint Working Group, Kimura, Matsushima, Mega, Mendell, Ogata, Ogawa, Oldgren, Oldgren, Patel, Sardar, Savelieva, Shen, Tanahashi, Tanigawa, Wong   +29 more
core   +1 more source

Underutilization of anticoagulants in patients with nonvalvular atrial fibrillation in the era of non-vitamin K antagonist oral anticoagulants

International Journal of Arrhythmia, 2022
Non-vitamin K antagonist oral anticoagulants (NOACs) are preferred over vitamin K antagonists (VKAs) as oral anticoagulant (OAC) therapy in patients with nonvalvular atrial fibrillation (NVAF).
Susin Park, N. Je
semanticscholar   +1 more source

Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition and Cancer Risk: Insights from a Large Propensity‐Matched Cohort Study

Clinical Pharmacology &Therapeutics, EarlyView.
Proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibodies (mAbs) lower LDL cholesterol and may influence cancer through immunomodulatory pathways. However, their effect on human cancer incidence remains unknown. We conducted a retrospective, propensity score‐matched study (Clalit Health Services, Israel, 2010–2023) comparing PCSK9 ...
Inbar Nardi Agmon, Chen Gurevitz, Tzippy Shochat, Shiri Kushnir, Guy Witberg, Amos Levi, Dan Gilon, Ran Kornowski, Paaladinesh Thavendiranathan, Husam Abdel Qadir, Zaza Iakobishvili   +10 more
wiley   +1 more source

Atrial high-rate episodes: prevalence, stroke risk, implications for management, and clinical gaps in evidence [PDF]

, 2019
Self-terminating atrial arrhythmias are commonly detected on continuous rhythm monitoring, e.g. by pacemakers or defibrillators. It is unclear whether the presence of these arrhythmias has therapeutic consequences.
Bertaglia, E, Blank, B, Blomström-Lundqvist, C, Brandes, A, Cabanelas, N, et al.   +4 more
core   +1 more source

Incident heart failure: comparing management and outcome in primary and hospital settings in Western Sweden 2008–2017

ESC Heart Failure, Volume 12, Issue 2, Page 832-838, April 2025.
Abstract Aim Heart failure (HF) is a highly prevalent condition managed in both primary care (PC) and hospital care (HC)‐based settings. HF patients managed in these two settings may differ in their demography, comorbidities and outcomes, so we aimed to compare the patient management in PC and HC in the Västra Götaland Region (VGR) in Sweden.
Xiaojing Chen, Aldina Pivodic, Maria Schaufelberger, Annika Rosengren, Michael Fu   +4 more
wiley   +1 more source